An anticancer compound is disclosed which is represented by the formula
wherein one of R1 and R2 is a phenyl-lower alkyl optionally having a substituent, phenyl-lower alkenyl or naphthyl-lower alkyl, the other of R1 and R2 is hydrogen or acyl, and R3 is hydrogen, acyl or tetrahydrofuranyl, or represented by the formula
wherein Rx is an optionally substituted pyridyl, Y is arylene and a is a known 5-fluorouracil derivative residue which can be converted to 5-fluorouracil in vivo and which is linked to the carbonyl by an ester or amide linkage.
公开了一种抗癌化合物,该化合物由式表示,其中 R1 和 R2 中的一个是可选具有取代基的
苯基-低级烷基、
苯基-低级
烯基或
萘基-低级烷基,R1 和 R2 中的另一个是
氢或酰基,R3 是
氢、酰基或
四氢呋喃基,或由式表示,其中 Rx 是可选取代的
吡啶基,Y 是芳基,a 是已知的 5-
氟尿
嘧啶衍
生物残基,该残基可在体内转化为 5-
氟尿
嘧啶,并通过
酯或
酰胺连接与羰基相连。